報告包：Claudin 18.2 標靶免疫治療

Report Package: Claudin 18.2-Targeted Immunotherapeutics

出版日期: 2024年04月30日 | 出版商:

La Merie Publishing | 英文 314 Pages | 訂單完成後即時交付

價格

簡介目錄

Claudin18.2是一種高度特異性的細胞表面分子，不僅在原發性胃癌中異常表達，而且在胰腺癌和食道癌等其他實體癌中也經常異常表達。 Claudin18.2 作為癌症標靶引起了人們的極大興趣，用於開發針對 Claudin18.2 本身的免疫療法候選藥物。 Claudin18.2 不僅有望成為一種有效的治療方法，還能夠應用多種藥物療法來產生候選化合物。在日本批准第一個針對 Claudin18.2 的免疫療法後，至少有 44 個候選藥物處於臨床階段，10 個候選藥物處於臨床前或 IND/CTA 開發階段。

本報告包□□從行業角度（2023年（截至8月））詳細分析了針對Claudin18.2的免疫療法的行業格局、利益相關者、藥物模式、管道、商機等。此外，我們截至 2024 年 4 月的競爭分析考察了 Claudin18.2 標靶免疫療法候選藥物的最新競爭領域。

Claudin18.2 (CLDN18.2) 標靶裸單株抗體
CLDN18.2標靶抗體藥物偶聯物
CLDN18.2靶向CAR-T細胞/NK細胞
CLDN18.2標靶T細胞募集雙特異性抗體
CLDN18.2/PD-L1標靶雙特異性抗體
CLDN18.2□4-1BB (CD137) 標靶雙特異性抗體
針對 CLDN18.2/CD47/SIRP-α 或 CD8 的雙特異性抗體

簡介目錄

Product Code: LMFR0040

Claudin18.2 is a highly specific cell surface molecule that is often abnormally expressed in primary gastric cancer as well as in other solid tumors such as pancreatic and esophageal cancers. Claudin 18.2 has gained considerable interest as a cancer target for development of claudin 18.2-targeted immunotherapy candidates. Apart from providing promise as an effective therapy, it also allows the application of a wide variety of drug modalities to generate development candidates. After approval in Japan of the first immunotherapy against claudin 18.2, the pipeline is packed with at least 44 candidates in the clinical stage and ten in the non-clinical or IND/CTA development stage.

This report package includes a full report of August 2023 analyzing in depth the landscape of claudin 18.2-targeted immunotherapy regarding stakeholders, drug modalities, pipeline and business opportunities from an industry perspective. The competitor analysis of April 2024 updates the competitive field of CLDN18.2-targeted immunotherapy candidates.